The EU Buried Dental Amalgam. U.S. Dentists Are Acting Like the Petition Filed Against Them Doesn't Exist.

The European Union eliminated dental amalgam as a routine restorative material on January 1, 2025, citing its Zero Pollution Action Plan and projections that the ban would prevent roughly 10 tonnes of mercury from entering the environment by 2030. Then, in August 2025, the International Academy of Oral Medicine and Toxicology (IAOMT) and Dental Amalgam Mercury Solutions (DAMS Inc.) submitted a formal Petition for Reconsideration to the FDA, requesting either an outright ban on encapsulated mercury fillings or their reclassification from Class II to Class III devices. The U.S. dental establishment has largely responded with silence. That silence is now a liability.

The failure to treat this as an imminent operational issue — rather than a distant policy debate — isn't just strategically short-sighted. It ignores a convergence of regulatory momentum, patient demand data, and the FDA's own published guidance that collectively point to one outcome: amalgam's viable window in U.S. practice is closing faster than most providers are planning for.

What the EU's January 2025 Prohibition Actually Means as a U.S. Preview

The EU ban isn't a soft phase-down with generous carve-outs. As finalized by the Council in May 2024, dental amalgam exports were prohibited from January 1, 2025. Import and manufacturing prohibitions take effect July 1, 2026. The only permitted exception is when a practitioner deems amalgam "strictly necessary" for a patient's specific medical needs — a high bar that makes amalgam a last-resort material, not a standard one.

U.S. dentists who view the EU as a geopolitically distant regulator should reconsider that framing. The EU's prohibition follows a well-worn path: Europe moves first on mercury phase-outs, the U.S. follows. The FDA already banned mercury in topical antiseptics, OTC laxatives, and skin-lightening products following analogous international pressure. The Minamata Convention on Mercury, which the U.S. ratified in 2013, committed signatory nations to a phase-down of dental amalgam — a commitment that the current regulatory posture has barely begun to honor. The EU action gives the FDA political cover and international precedent to act. The IAOMT petition gives it a formal procedural trigger.

The FDA Petition Is on the Table — Here's What the Agency's Own Warnings Already Signal

The IAOMT/DAMS petition didn't land in a vacuum. The FDA's own 2020 guidance, which the petition explicitly cites, already recommended against amalgam use for pregnant women, nursing mothers, children under six, people with neurological conditions such as Alzheimer's, MS, and Parkinson's, and those with kidney impairment. The agency acknowledged that amalgam fillings release mercury vapor that "may be harmful" to these groups.

That guidance, read honestly, already restricts amalgam to a narrower patient population than most practices currently apply it to. The IAOMT petition simply requests the FDA complete the logical arc of its own reasoning: if amalgam is contraindicated for high-risk groups, and mercury is a cumulative neurotoxin comprising approximately 50% of amalgam by weight, the risk threshold for a population-level ban isn't far beyond what the agency has already conceded.

Practices waiting for a formal FDA ruling before taking action are misreading the timeline. The petition's submission creates a formal docket. The FDA is legally obligated to respond. The question for practice owners isn't whether the agency will eventually restrict amalgam further — it's whether their operations will be ready when it does.

Composite Alternatives Aren't a Drop-In Replacement: The Hidden Training and Cost Gap

The most dangerous assumption driving inaction is that converting from amalgam to composite is a materials swap. It isn't. Posterior composite restorations (CDT codes D2391-D2394) require a fundamentally different technique stack: incremental layering, LED or UV curing equipment, adhesive bonding protocols with moisture control, and substantially more chairtime than packing amalgam. Clinicians trained primarily on amalgam placement — and there are many still practicing who developed their posterior restoration technique before composite was mainstream — will need formal retraining to achieve consistent margins and prevent microleakage and secondary caries.

The continuing education infrastructure exists. Spear Education, the Dawson Academy, and Cosmedent all offer hands-on composite mastery curricula. But the cost is real: course fees, travel, temporary productivity loss, and the investment in curing lights, bonding agents, and composite inventories across multiple shade guides. Amalgam's predictability came partly from its material tolerance for technique variation. Composite forgives less.

Material sourcing is an additional friction point. Amalgam capsules are shelf-stable, generic, and low-cost, typically $75 to $200 in chair fees. Composite systems from premium brands carry higher per-unit costs, and practices that haven't established preferred supplier relationships will pay spot pricing during any supply chain disruption. A ban announcement — even a phased one — tends to create exactly those disruptions.

Patient Demand Has Already Moved — the Regulatory Clock Is Just Catching Up

The market data reframes the amalgam transition from a compliance burden into a competitive positioning question. Amalgam restoration placements in the U.S. collapsed from 21.8% of restorations in 2017 to just 4.1% in 2023, an 80% decline driven largely by patient preference, not regulatory compulsion. Over 70% of younger patient demographics now prefer providers who use safe and sustainable materials, according to market research cited by Number Analytics. The mercury-free dental materials market, valued at $1.15 billion in 2024, is projected to reach $2.6 billion by 2033 at a 10.5% CAGR.

This trajectory means practices that haven't already repositioned around mercury-free dentistry aren't just behind on regulatory compliance — they're behind on patient acquisition. The patient who is already asking about amalgam alternatives before their appointment is the same patient who reads reviews, refers family members, and expects their provider to be fluent in the safety conversation. Practices that can't provide that fluency are sending a signal about clinical currency that patients notice.

Insurance Coding, Material Sourcing, and the Operational Realities of Going Mercury-Free

The insurance coding dimension is where many practices will feel the transition most acutely in their revenue cycle. A substantial portion of payers still apply the "alternate benefit clause" to posterior composite restorations, reimbursing at amalgam rates regardless of what material was placed. When a D2394 (four-surface posterior composite) is submitted, payer logic often auto-downgrades to a D2161 amalgam code, leaving the practice to absorb the difference or bill the patient.

Navigating this requires proactive documentation practices: detailed clinical narratives establishing medical necessity for composite over amalgam, intraoral radiographs attached to claims, and in many cases, direct negotiation with payers to update fee schedules. Practices converting to fully mercury-free operations without addressing this coding gap will see margin compression that makes the transition look more costly than it is. The operational fix is knowable — but it requires implementing it before the regulatory mandate creates a deadline-driven scramble.

The Practices That Transition Early Will Win the Patients Already Asking

The amalgam phase-out presents a bifurcated competitive outcome. Practices that complete the operational conversion now — training staff on posterior composite technique, renegotiating payer schedules, establishing material supply chains, and building patient-facing messaging around mercury-free protocols — will be positioned to absorb patients from practices that delay. And delay is the modal response: most practices currently placing fewer than 5% amalgam restorations haven't formalized the gap into a true mercury-free protocol, haven't trained front desk staff on the patient communication, and haven't addressed the insurance coding exposure.

Dr. Jack Kall, IAOMT Executive Chair, put the regulatory logic plainly: "It is time to complete the process and ban mercury fillings outright, aligning with global standards set by the European Union and numerous other countries." For U.S. practice owners, the honest reading of that statement isn't alarmism. It's a project plan with a deadline they don't yet know but can estimate. The EU moved in January 2025. The FDA petition landed in August 2025. The practices building their composite workflows in early 2026 will be the ones who look prescient when the formal restriction arrives — and the ones collecting new patients from every practice that waited.